Abacavir for salvage or intensification
- PMID: 11366111
Abacavir for salvage or intensification
Abstract
AIDS: Abacavir (Ziagen), a newly approved nucleoside analog, could be one of the most potent antiretrovirals available. Most of the clinical trials on abacavir have focused on patients who have never been treated for HIV, and they have responded well to the drug. The drug is not expected to be as effective in patients who have exhausted treatment options, as was demonstrated by Glaxo study CNA2007. The most common side effect of abacavir was skin rash. Some participants also reported systemic flu-like symptoms. Abacavir shows promise in intensification therapies where a drug is added to an established regimen that is not working, and in salvage therapies where patients have few treatment options remaining.
Similar articles
-
Ziagen (abacavir) approved: caution essential.AIDS Treat News. 1999 Jan 8;(No 310):1, 3-6. AIDS Treat News. 1999. PMID: 11366148
-
Abacavir at last.GMHC Treat Issues. 1998 Mar;12(3):9. GMHC Treat Issues. 1998. PMID: 11365394
-
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.Antivir Ther. 2001 Jun;6(2):135-42. Antivir Ther. 2001. PMID: 11491418 Clinical Trial.
-
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.Antivir Ther. 2007;12(5):695-703. Antivir Ther. 2007. PMID: 17713153 Review.
-
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review.Med Sci Monit. 2006 Dec;12(12):RA269-276. Epub 2006 Nov 23. Med Sci Monit. 2006. PMID: 17136016 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical